BioNTech: 'We Could Produce New COVID Variant Vaccine In Six Weeks'
Vaccine Developer Is Confident Existing Vaccine Still Works
Executive Summary
The speed of the new messenger RNA platforms could once again come to the rescue, but the expectation is that existing vaccines should remain effective against the emerging strain.
You may also be interested in...
US COVID-19 Vaccination Rollout On Track After Early Bumps, J.P. Morgan Panelists Say
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.
Pfizer/BioNTech COVID-19 Vaccine Wins EU Green Light
The first COVID-19 vaccine will shortly be available to the EU member states. The European Medicines Agency says that uncertainties remain over the ability of the vaccine to prevent transmission of the coronavirus and whether the new variant strain will render this and other vaccines less effective.
Pfizer/BioNTech COVID-19 Vaccine Wins EU Approval
The first COVID-19 vaccine will shortly be available to the EU member states, after the European Commission today approved Pfizer/BioNTech's BNT162b2 just hours after the European Medicines Agency issued a positive opinion on the product. The EMA says that uncertainties remain over the ability of the vaccine to prevent transmission of the coronavirus and whether the new variant strain will render this and other vaccines less effective.